The New Strategy for Pharmacological Treatment in People With Schizophrenia
Phase 4
- Conditions
- Schizophrenia
- Interventions
- Registration Number
- NCT00352339
- Lead Sponsor
- Inje University
- Brief Summary
Switching from Risperidone to Aripiprazole in early stage of pharmacotherapy will demonstrate the same efficacy as compared to risperidone continuation treatment in the treatment of schizophrenia.
- Detailed Description
It has been thought that D2 Blocking agent is necessary in acute as well as maintenance phase of pharmacological treatment of patients with schizophrenia. However, this classical strategy produces long term adverse events of drug such as TD, osteoporosis and some metabolic syndrome. To overcome these adverse events, new strategy for pharmacological treatment is needed.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
- Schizophrenia, DSM-IV
- Acute phase
Exclusion Criteria
- Refractory Schizophrenia
- Substance Abuse
- High risk for suicide
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Aripiprazole Rispridoen and Aripiprazole switching group (from risperidone to aripiprazole) Risperidone Risperidne Start with risperidone and keep it through the end of study Abilify Abilify Start with aripiprazole and keep it through the end of study
- Primary Outcome Measures
Name Time Method SANS(Scale for the Assessment of Negative Symptoms) 12 weeks
- Secondary Outcome Measures
Name Time Method SARS(Simpson-Angus Rating Scale) 12 weeks Drug Attitude Inventory 12 weeks Side effect checklist 12 weeks
Trial Locations
- Locations (2)
Dongrae Hospital
🇰🇷Busan, Korea, Republic of
Dongseo Hospital
🇰🇷Masan, Korea, Republic of